Evidence map›Paper›PMID 42301423›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Detailed pharmacokinetic features of a novel bis-boron

Guobing Liu, Hongrong Xu, Jing Lv, Yunze Xie, Lichao Zhang, Denis Agostini, Florent L Besson, Axel Rominger, Akram Al-Ibraheem, Jiefu Zheng and 3 more

Abstract readClinical Trial, Phase I
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Guobing Liu *Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Hongrong Xu *Department of Clinical Pharmacology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Jing Lv *Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Yunze XieDepartment of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Lichao ZhangDepartment of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Denis AgostiniDepartment of Nuclear Medicine, University Hospital of Caen and Normandie Université, Caen, 14000, France.
Florent L BessonDepartment of Nuclear Medicine‑Molecular Imaging, AP‑HP, DMU Smart Imaging, Hôpitaux Universitaires Paris‑Saclay, CHU Bicêtre, Paris, 92140, France.
Axel RomingerDepartment of Nuclear Medicine, Bern University Hospital, Inselspital, University of Bern, Bern, CH-3010, Switzerland.
Akram Al-IbraheemDepartment of Nuclear Medicine and PET/CT, King Hussein Cancer Center (KHCC), Amman, 11941, Jordan.
Jiefu ZhengDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology and Medical Imaging, University of Virginia School of Medicine, Charlottesville, VA, 22908-0170, USA.
Lorenzo NardoDepartment of Radiology, University of California Davis Medical Center, Sacramento, CA, 95817, USA.
Xuening LiDepartment of Clinical Pharmacology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China. li.xuening@zs-hospital.sh.cn.
Hongcheng ShiDepartment of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai, 200032, China. shi.hongcheng@zs-hospital.sh.cn.ORCID 0000-0001-7457-876X

Funding

The Chinese National Key Clinical Specialty Program YWP2022-007The Innovative Medical Device Application Demonstration Program of Shanghai Municipal Commission of Economy and Informatization 23SHS01200 and 23SHS01200-01The Key Program of Ministry of Industry and Information Technology of China CEIEC-2022-ZM02-0219The Shanghai 2024 "Explorer" program 24TS1411100
6 · The paper itself

Abstract

purposeTo characterize the systemic and organ-specific pharmacokinetics (PK) of a novel bis-boron tracer, [

methodsTen healthy volunteers underwent 60-minute dynamic total-body [

results[

conclusion[ CLINICAL

trial registrationThis is a phase I clinical trial approved by the National Medical Products Administration of China and was registered at www.chinadrugtrials.org.cn (CTR20233997).

Indexed as

Boron CompoundsFluorine RadioisotopesPositron-Emission TomographyRadiopharmaceuticalsWhole Body ImagingAdultFemaleHealthy VolunteersHumansMaleMiddle AgedTissue DistributionYoung AdultBoron CompoundsFluorine RadioisotopesRadiopharmaceuticalsBoramino acidDynamic imagingPharmacokineticsPositron emission tomography

Identifiers

PMID42301423

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.